A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

מצבים רפואיים

Obesity

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Chambliss Clinical Trials, LLC, Montgomery, Alabama, United States

  • FDRC, Costa Mesa, California, United States

  • Los Angeles Institute for Metabolic Research, Los Angeles, California, United States

  • Encore Medical Research LLC, Hollywood, Florida, United States

  • South Broward Research LLC, Miramar, Florida, United States

  • West Orange Endocrinology, Ocoee, Florida, United States

  • Cedar-Crosse Research Center, Chicago, Illinois, United States

  • Great Lakes Clinical Trials, Chicago, Illinois, United States

  • Midwest Inst For Clin Res, Indianapolis, Indiana, United States

  • L-MARC Research Center, Louisville, Kentucky, United States

  • Endo And Metab Cons, Rockville, Maryland, United States

  • StudyMetrix Research LLC, City of Saint Peters, Missouri, United States

  • Great Lakes Medical Research, Westfield, New York, United States

  • KDCILM, LLC & Accellacare US, Inc., Wilmington, North Carolina, United States

  • Family Practice Center of Wadsworth Inc., Wadsworth, Ohio, United States

  • UPA Ctr Weight and Eating Dis, Philadelphia, Pennsylvania, United States

  • Clinical Res Collaborative, Cumberland, Rhode Island, United States

  • Holston Medical Group_Bristol, Bristol, Tennessee, United States

  • Holston Medical Group, Kingsport, Tennessee, United States

  • Clinical Research Associates, Nashville, Tennessee, United States

  • PlanIt Research, PLLC, Houston, Texas, United States

  • Pinnacle Clinical Research, San Antonio, Texas, United States

  • National Clin Res Inc., Richmond, Virginia, United States

  • Rainier Clin Res Ctr Inc, Renton, Washington, United States

  • Isis Clinical Res. Ctr P.S.C., Guaynabo, Puerto Rico

מובילי המחקר
  • Clinical Transparency (dept. 2834)

    Study Director

    Novo Nordisk A/S